FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:299-300 July 19, 2007 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Advanced tumors cannot be cured with single drugs. They often are resistant to single agents, and even if they are initially sensitive, their molecular heterogeneity usually guarantees the secondary outgrowth of rare cells that are resistant. In contrast, drug combinations can cure specific types of cancers even at advanced stages; this observation has spurred the development of combination chemotherapy for most types of cancer during the past half century. Examples of effective therapeutic combinations include doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin's lymphoma and bleomycin, etoposide, and cisplatin for testicular cancer. Most combinations seldom cure disease, however, and their identification . . . [Full Text of this Article]

Source Information

From the Massachusetts General Hospital Cancer Center and Harvard Medical School — both in Boston; and the Broad Institute of the Massachusetts Institute of Technology and Harvard University and the Harvard Stem Cell Institute — both in Cambridge, MA.

This article has been cited by other articles:

• Mayer, L. D., Janoff, A. S. (2007). Optimizing Combination Chemotherapy by Controlling Drug Ratios. Mol. Interv. 7: 216-223 [Abstract] [Full Text]